Advertisement

Obesity Surgery

, Volume 28, Issue 1, pp 187–194 | Cite as

Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features

  • Everton CazzoEmail author
  • Laísa Simakawa Jimenez
  • Martinho Antonio Gestic
  • Murillo Pimentel Utrini
  • Fábio Henrique Mendonça Chaim
  • Felipe David Mendonça Chaim
  • José Carlos Pareja
  • Elinton Adami Chaim
Original Contributions

Abstract

Objective

This study aims to investigate the correlation between features of NAFLD among individuals with morbid obesity and the surrogate IR markers homeostasis model assessment (HOMA), product of triglycerides and glucose (TyG), and triglyceride-to-high-density-lipoprotein ratio (TG/HDL-c).

Methods

A cross-sectional study, which enrolled 89 individuals who consecutively underwent bariatric surgery from February through December 2015, was conducted. NAFLD was assessed through histological examination of liver biopsies and correlated with the values of HOMA, TyG, and TG/HDL-c and their respective cutoff points for insulin resistance (IR).

Results

xThe prevalence of liver steatosis was 68.5%; the affected individuals presented significantly higher fasting glucose levels (p < 0.01) and hemoglobin A1c (p < 0.01), and a significantly higher prevalence of type 2 diabetes mellitus (T2DM) (p < 0.001). Fibrosis occurred in 66.3% of the individuals and was significantly associated with higher levels of HbA1c (p < 0.05) and a higher prevalence of T2DM (p < 0.05). Steatohepatitis was present in 64% of the individuals and was significantly associated with older age (p < 0.05), higher levels of fasting glucose (p < 0.05), and a higher prevalence of T2DM (p < 0.001). After Bonferroni’s adjustment, T2DM was significantly correlated with fibrosis (p < 0.01) and steatohepatitis (p < 0.001) and older age was significantly correlated with fibrosis (p < 0.05). T2DM was the only variable independently associated with fibrosis and steatohepatitis (p < 0.05 in both cases).

Conclusion

T2DM was a significant predictor of NAFLD features among individuals undergoing bariatric surgery; higher Hb A1c was correlated with fibrosis. T2DM was independently associated with fibrosis and steatohepatitis. HOMA, TyG, and TG/HDL-c ratio did not present significant associations with NAFLD.

Keywords

Fatty liver Obesity Insulin resistance Bariatric surgery Biomarkers 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Statement of Informed Consent

Informed consent was obtained from all individual participants included in the study.

Statement of Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical. Metab Clin Implications Hepatol. 2010;51(2):679–89.Google Scholar
  2. 2.
    Jayakumar S, Harrison SA, Loomba R. Noninvasive markers of fibrosis and inflammation in nonalcoholic fatty liver disease. Curr Hepatol Rep. 2016;15(2):86–95.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58(5):1007–19.CrossRefPubMedGoogle Scholar
  4. 4.
    Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Macut D, Tziomalos K, Božić-Antić I, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016;31(6):1347–53.CrossRefPubMedGoogle Scholar
  8. 8.
    El-Karaksy HM, El-Raziky MS, Fouad HM, et al. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children. Diabetes Metab Syndr. 2015;9(2):114–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Cazzo E, Pareja JC, Chaim EA. Weight loss surgery and the surrogate insulin resistance markers HOMA, TyG, and TG/HDL-c in relation to metabolic syndrome. In: Preedy VR, Rajendram R, Martin CR. London: Academic Press; 2017. pp.325–31.Google Scholar
  10. 10.
    Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr. 1992;55(2 Suppl):615S–9S.Google Scholar
  11. 11.
    Chaim EA, Pareja JC, Gestic MA, et al. Preoperative multidisciplinary program for bariatric surgery: a proposal for the Brazilian public health system. Arq Gastroenterol. 2017;54(1):70–4.CrossRefPubMedGoogle Scholar
  12. 12.
    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMedGoogle Scholar
  13. 13.
    International Diabetes Federation. Global guideline for type 2 diabetes. Brussels: IDF. 2012: 1–123.Google Scholar
  14. 14.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides x glucose versus triglyceride/high-density lipoprotein cholesterol. Metabolism. 2011;60(12):1673–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Geloneze B, Vasques AC, Stabe CF, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol. 2009;53(2):281–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Vasques AC, Novaes FS, de Oliveira MS, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98–e100.CrossRefPubMedGoogle Scholar
  19. 19.
    Karelis AD, Pasternyk SM, Messier L, et al. Relationship between insulin sensitivity and the triglyceride-HDL-C ratio in overweight and obese postmenopausal women: a MONET study. Appl Physiol Nutr Metab. 2007;32(6):1089–96.CrossRefPubMedGoogle Scholar
  20. 20.
    Morita S, Neto Dde S, Morita FH, et al. Prevalence of non-alcoholic fatty liver disease and steatohepatitis risk factors in patients undergoing bariatric surgery. Obes Surg. 2015;25(12):2335–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Gómez-Ambrosi J, Moncada R, Valentí V, et al. Cardiometabolic profile related to body adiposity identifies patients eligible for bariatric surgery more accurately than BMI. Obes Surg. 2015;25(9):1594–603.CrossRefPubMedGoogle Scholar
  22. 22.
    Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104(4):861–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35(4):873–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int. 2016;36(2):275–83.CrossRefPubMedGoogle Scholar
  25. 25.
    Cazzo E, da Silva FP, Pareja JC, et al. Predictors for weight loss failure following Roux-en-Y gastric bypass. Arq Gastroenterol. 2014;51(4):328–30.CrossRefPubMedGoogle Scholar
  26. 26.
    Yamazaki H, Tsuboya T, Tsuji K, et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015;38(9):1673–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Cazzo E, Jimenez LS, Gallo Fde F, et al. Influence of type 2 diabetes mellitus on liver histology among morbidly obese individuals. A cross-sectional study. Sao Paulo Med J. 2016;134(1):79–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes. 2010 May 15;1(2):36–47.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Antuna-Puente B, Disse E, Rabasa-Lhoret R, et al. How can we measure insulin sensitivity/resistance? Diabetes Metab. 2011;37(3):179–88.CrossRefPubMedGoogle Scholar
  30. 30.
    Cazzo E, Callejas-Neto F, Pareja JC, et al. Correlation between post over preoperative surrogate insulin resistance indexes’ ratios and reversal of metabolic syndrome after Roux-en-Y gastric bypass. Obes Surg. 2014;24(6):971–3.CrossRefPubMedGoogle Scholar
  31. 31.
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.CrossRefPubMedGoogle Scholar
  32. 32.
    Skrha J, Haas T, Sindelka G, et al. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab. 2004;89(1):135–41.CrossRefPubMedGoogle Scholar
  33. 33.
    Malita FM, Messier V, Lavoie JM, et al. Comparison between several insulin sensitivity indices and metabolic risk factors in overweight and obese postmenopausal women: a MONET study. Nutr Metab Cardiovasc Dis. 2010;20(3):173–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.CrossRefPubMedGoogle Scholar
  35. 35.
    Giannini C, Santoro N, Caprio S, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care. 2011;34(8):1869–74.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kelley DE. Skeletal muscle triglycerides: an aspect of regional adiposity and insulin resistance. Ann N Y Acad Sci. 2002;967:135–45.CrossRefPubMedGoogle Scholar
  37. 37.
    Tripathy D, Almgren P, Tuomi T, et al. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care. 2004;27(9):2204–10.CrossRefPubMedGoogle Scholar
  38. 38.
    Sumner AE, Finley KB, Genovese DJ, et al. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med. 2005;165(12):1395–400.CrossRefPubMedGoogle Scholar
  39. 39.
    Cruz MA, Cruz JF, Macena LB, et al. Association of the nonalcoholic hepatic steatosis and its degrees with the values of liver enzymes and homeostasis model assessment-insulin resistance index. Gastroenterol Res. 2015;8(5):260–4.CrossRefGoogle Scholar
  40. 40.
    Yang KC, Hung HF, Lu CW, et al. Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance. Sci Rep. 2016;6:27034.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ballestri S, Nascimbeni F, Romagnoli D, et al. The independent predictors of non-alcoholic steatohepatitis and its individual histological features: insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46(11):1074–87.CrossRefPubMedGoogle Scholar
  42. 42.
    Aller R, Izaola O, Ruiz-Rebollo L, et al. Predictive factors of non-alcoholic steatohepatitis: relationship with metabolic syndrome. Nutr Hosp. 2015;31(6):2496–502.PubMedGoogle Scholar
  43. 43.
    Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–22.CrossRefPubMedGoogle Scholar
  44. 44.
    Zhang S, Du T, Zhang J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):15.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Simental-Mendía LE, Simental-Mendía E, Rodríguez-Hernández H, et al. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women. Ann Hepatol. 2016;15(5):715–20.PubMedGoogle Scholar
  46. 46.
    Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(2):420–5.e1.CrossRefPubMedGoogle Scholar
  47. 47.
    Pacifico L, Bonci E, Andreoli G, et al. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis. 2014;24(7):737–43.CrossRefPubMedGoogle Scholar
  48. 48.
    Fukuda Y, Hashimoto Y, Hamaguchi M, et al. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int. 2016;36(5):713–20.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Everton Cazzo
    • 1
    Email author
  • Laísa Simakawa Jimenez
    • 1
  • Martinho Antonio Gestic
    • 1
  • Murillo Pimentel Utrini
    • 1
  • Fábio Henrique Mendonça Chaim
    • 1
  • Felipe David Mendonça Chaim
    • 1
  • José Carlos Pareja
    • 1
  • Elinton Adami Chaim
    • 1
  1. 1.Department of Surgery, Faculty of Medical SciencesState University of Campinas (UNICAMP)CampinasBrazil

Personalised recommendations